A Panel to Predict Long-term Outcome of Infliximab Therapy for Patients With Ulcerative Colitis

Arias, Maria Theresa; Casteele, Niels Vande; Vermeire, Séverine; Overstraeten, Anthony de Buck van; Billiet, Thomas; Baert, Filip; Wolthuis, Albert; Assche, Gert Van; Noman, Maja; Hoffman, Ilse; D’Hoore, André; Gils, Ann; Rutgeerts, Paul; Ferrante, Marc

doi:10.1016/j.cgh.2014.07.055

Cited by 161 publications

(118 citation statements)

References 24 publications

Supporting

Mentioning

109

Contrasting

Unclassified

Order By: Relevance

“…Although the effects of new drugs on the relapse of UC were reported recently (24)(25)(26)(27)(28)(29)(30), this effect was not observed in the current study about mesalazin. It is highly recommended to use new generations of UC drugs and increase visits of high risk patients for relapse in the region under study.…”

Section: Discussioncontrasting

confidence: 53%

Incidence of Ulcerative Colitis Relapse: A Prospective Cohort Study in Southern Iran

et al. 2016

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 53%

Incidence of Ulcerative Colitis Relapse: A Prospective Cohort Study in Southern Iran

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Recent reports indicate that CRP is not a suitable biomarker in patients with UC because CRP level is not consistently elevated in this clinical setting during the acute phase of the disease [24]. Contrary to this assertion, 1 study has reported the value of CRP in patients with severe UC during hospitalization [25], and another study has reported that the risk of surgery increased when CRP level was greater than 2.3 mg/dL in patients with pancolitis [26]. More interestingly, a combination of CRP levels, infliximab trough levels, and titers of antiinfliximab antibodies has been reported to predict relapse in patients with UC [27].…”

Section: Discussioncontrasting

confidence: 43%

Assessment of Long-Term Efficacy and Safety of Adalimumab in Patients with Ulcerative Colitis: Results from a 6-Year Real-World Clinical Practice

Sugimoto

Ikeya

Kato

et al. 2018

Dig Dis

View full text Add to dashboard Cite

Background: Although evidence for the short- to medium-term efficacy of adalimumab in ulcerative colitis (UC) patients is emerging, there are a limited number of reports on the long-term efficacy of adalimumab. This study was to understand baseline demographic features, which potentially could be risk factors for relapse or colectomy following induction of remission by adalimumab in UC patients. Additionally, factors affecting long-term outcomes were to be identified. Methods: Twenty-one patients with UC who had been treated with adalimumab were reviewed retrospectively. Comparative analyses were undertaken by factoring steroid withdrawal versus non-withdrawal, long-term remission versus relapse following remission, and requiring surgical intervention for UC versus surgery-free. Results: Adalimumab treatment was associated with steroid tapering in steroid-dependent cases in the long term. Of the 14 patients in whom clinical remission was achieved, the cumulative nonrelapse survival rate at 350 weeks was 43.8% and the cumulative nonoperative survival rate was 85.7%. Risk factors for surgery included intolerance to salicylates (p = 0.005) and past treatment with tacrolimus (p = 0.023). Conclusions: Adalimumab treatment was associated with long-term efficacy in patients with mild UC – patients achieved a high cumulative nonoperative survival rate over a long period of time, beyond 6 years.

show abstract

“…Despite its proven efficacy, up to 60 % of patients who have an initial response to anti-TNF therapy will then experience secondary loss of response, requiring dose escalation or a switch to another anti-TNF to recapture response [3,4]. Loss of clinical benefit can be due to an increased clearance of the drug in the presence or absence of anti-drug antibodies (ADAs) [5][6][7].…”

Section: Introductionmentioning

confidence: 99%

Cost-effectiveness of drug monitoring of anti-TNF therapy in inflammatory bowel disease and rheumatoid arthritis: a systematic review

et al. 2016

View full text Add to dashboard Cite

Background Therapeutic drug monitoring (TDM) of anti-TNF is increasingly used to manage inflammatory bowel diseases (IBD) and rheumatoid arthritis (RA). The costeffectiveness of this strategy is debated. Methods All studies comparing the cost-effectiveness of a TDM-based strategy and an empirical dose management of anti-TNF in IBD or RA were screened. Studies were identified through the MEDLINE electronic database (up to July 2016), and annual international meeting abstracts were also manually reviewed. Results Seven studies were included: two randomized controlled trials (RCTs) enrolling 332 patients [247 Crohn's disease (CD) and 85 ulcerative colitis (UC)] and five modeling approaches. Four studies included only CD patients, one included both CD and UC patients, and two included only RA patients. Three studies compared the cost-effectiveness of the two strategies in patients with secondary infliximab (IFX) failure (dose-escalation strategy), one in patients in remission on optimized IFX (deescalation strategy), one in patients starting adalimumab, and two in patients with clinical response to maintenance anti-TNF therapy. The two RCTs demonstrated that a TDM strategy led to major cost savings, ranging from 28 to 34 %. The three modeling approaches with regard to CD patients demonstrated cost savings ranging from $5396 over a 1-year period to €13,130 per patient at 5 years of follow-up. A TDM strategy also led to major cost savings in the two modeling approaches in RA patients. Conclusions Available evidence indicates that a TDM strategy leads to major cost savings related to anti-TNF therapy in both IBD and RA patients, with no negative impact on efficacy.

show abstract

A Panel to Predict Long-term Outcome of Infliximab Therapy for Patients With Ulcerative Colitis

Cited by 161 publications

References 24 publications

Incidence of Ulcerative Colitis Relapse: A Prospective Cohort Study in Southern Iran

Incidence of Ulcerative Colitis Relapse: A Prospective Cohort Study in Southern Iran

Assessment of Long-Term Efficacy and Safety of Adalimumab in Patients with Ulcerative Colitis: Results from a 6-Year Real-World Clinical Practice

Cost-effectiveness of drug monitoring of anti-TNF therapy in inflammatory bowel disease and rheumatoid arthritis: a systematic review

Contact Info

Product

Resources

About